Article

Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns

2024-10-17

Abstract excerpt

<h4>Background</h4> The neonatal immune system is uniquely poised to generate broadly neutralizing antibodies (bnAbs) and thus infants are ideal for evaluating HIV vaccine candidates. We present the design and safety of a novel glucopyranosyl lipid A (GLA)-stable emulsion (SE) adjuvant admixed with a first-in-infant CH505 transmitter-founder (CH505TF) gp120 immunogen designed to induce precursors for bnAbs against...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c184140-8f8e-5f18-b867-12a9d2752589
DOI: 10.1101/2024.10.15.24315548

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newbornsDOI 10.1101/2024.10.15.24315548Read

Potential for Maternally Administered Vaccine for Infant Group B StreptococcusSemantic proximity Read

Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humansSemantic proximity Read

Timing of Maternal Vaccination Against COVID-19 for Effective Protection of Neonates: A Cohort Study from South KoreaSemantic proximity Read

The safety and immunogenicity of a combined pertussis containing vaccine Tdap for HIV infected pregnant women and their newborns (WoMANPOWER) – A study protocol for a randomized clinical trialSemantic proximity Read

Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025Semantic proximity Read

Vaccine effectiveness against mild and severe disease in pregnant mothers and their infants in EnglandSemantic proximity Read

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern AfricaSemantic proximity Read

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.Semantic proximity Read

Preventing breastmilk HIV transmission using broadly neutralising monoclonal antibodies: one size does not fit allSemantic proximity Read

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countriesSemantic proximity Read

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trialSemantic proximity Read

Vaccination induces HIV broadly neutralizing antibody precursors in humans.Semantic proximity Read